Skip to main content
. 2023 Dec 1;38(6):1149–1154. doi: 10.1038/s41433-023-02849-6

Fig. 3. Mean change of vision and macular anatomy in the SUSHI study.

Fig. 3

Nine refractory nAMD patients received a single intravitreal injection of umedaptanib pegol at doses of 0.2 (cohort 1), 1.0 (cohort 2) or 2.0 mg (cohort 3) in the eye under study. a Change of central subfield thickness (CST) monitored by OCT. b Change of best-corrected visual acuity (BCVA) monitored by EDTRS letters. Error bars represent standard error.